T-cell engagers (TCEs) offer a new frontier by directly linking T-cells to cancer cells via specific tumor antigens (like PSMA, STEAP1, and DLL3), bypassing traditional immune recognition. This evidence concerns the gene FOLH1 and neoplasm.